TY - JOUR
T1 - Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma
AU - Bateman, Eric D.
AU - Khan, Asif H.
AU - Xu, Yingxin
AU - Guyot, Patricia
AU - Chao, Jingdong
AU - Kamat, Siddhesh
AU - Rowe, Paul
AU - Burnett, Heather
AU - Msihid, Jerome
AU - Weinreich, David
AU - Pavord, Ian D.
N1 - Funding Information:
This work was supported by Sanofi and Regeneron Pharmaceuticals, Inc.
Funding Information:
We would like to thank Nora Crikelair, Marcella Ruddy, Nikhil Amin, Neil M. H. Graham at Regeneron Pharmaceuticals, Inc. and Dianne Barry, Ariel Teper, Heribert W. Staudinger, Naimish Patel, Isabelle Dubroca, Loubna Haddy at Sanofi. Evidera: Kyle Fahrbach, and Binod Neupane their support. This research was sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The authors received writing/editorial support in the preparation of this manuscript provided by Xiomara V. Thomas, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Publisher Copyright:
© 2020
PY - 2022/1
Y1 - 2022/1
N2 - Background: Currently, five biologic treatment options are available for use in patients with uncontrolled persistent asthma: three interleukin (IL)-5 antagonists, which either bind to the anti-IL-5 ligand (mepolizumab, reslizumab) or to the IL-5 receptor (benralizumab); one anti-immunoglobulin E (anti-IgE) therapy (omalizumab); and one anti-IL-4/IL-13 therapy (dupilumab). To date, no comparative data from head-to-head clinical trials are available for these biologics. Objective: An indirect treatment comparison (ITC) of dupilumab versus each of the anti-IL-5 and anti-IgE therapies using the endpoints of annualized severe asthma exacerbation rates and change in pre-bronchodilator forced expiratory volume in 1 s (FEV1). Methods: Embase®, MEDLINE®, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for studies published between January 1, 1980 and March 25, 2019. Eligible articles included randomized controlled trials (RCTs) in patients aged ≥ 12 years with persistent/uncontrolled asthma using at least medium-to-high dose inhaled corticosteroid plus long-acting β2-agonist with add-on biologic therapy. Bucher ITCs were performed to compare subgroups of dupilumab patients with the anti-IL-5s and anti-IgE trial populations. Results: Fourteen RCTs were included in the analyses. The matched dupilumab subgroups were associated with greater reductions in annualized severe exacerbation rates compared with benralizumab, mepolizumab, reslizumab, and omalizumab (54%, 28%, 38%, and 26% greater reduction, respectively). A greater improvement in FEV1 was also observed for dupilumab at week 12 and/or week 24/52 than for the other biologics (0.06–0.14 L). Conclusion: In this ITC, dupilumab was associated with lower severe asthma exacerbation rates and greater improvements in lung function than anti-IL-5s and omalizumab.
AB - Background: Currently, five biologic treatment options are available for use in patients with uncontrolled persistent asthma: three interleukin (IL)-5 antagonists, which either bind to the anti-IL-5 ligand (mepolizumab, reslizumab) or to the IL-5 receptor (benralizumab); one anti-immunoglobulin E (anti-IgE) therapy (omalizumab); and one anti-IL-4/IL-13 therapy (dupilumab). To date, no comparative data from head-to-head clinical trials are available for these biologics. Objective: An indirect treatment comparison (ITC) of dupilumab versus each of the anti-IL-5 and anti-IgE therapies using the endpoints of annualized severe asthma exacerbation rates and change in pre-bronchodilator forced expiratory volume in 1 s (FEV1). Methods: Embase®, MEDLINE®, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for studies published between January 1, 1980 and March 25, 2019. Eligible articles included randomized controlled trials (RCTs) in patients aged ≥ 12 years with persistent/uncontrolled asthma using at least medium-to-high dose inhaled corticosteroid plus long-acting β2-agonist with add-on biologic therapy. Bucher ITCs were performed to compare subgroups of dupilumab patients with the anti-IL-5s and anti-IgE trial populations. Results: Fourteen RCTs were included in the analyses. The matched dupilumab subgroups were associated with greater reductions in annualized severe exacerbation rates compared with benralizumab, mepolizumab, reslizumab, and omalizumab (54%, 28%, 38%, and 26% greater reduction, respectively). A greater improvement in FEV1 was also observed for dupilumab at week 12 and/or week 24/52 than for the other biologics (0.06–0.14 L). Conclusion: In this ITC, dupilumab was associated with lower severe asthma exacerbation rates and greater improvements in lung function than anti-IL-5s and omalizumab.
KW - Asthma
KW - Biologics
KW - Dupilumab
KW - Exacerbations
KW - FEV
KW - Lung function
UR - http://www.scopus.com/inward/record.url?scp=85086923426&partnerID=8YFLogxK
U2 - 10.1016/j.rmed.2020.105991
DO - 10.1016/j.rmed.2020.105991
M3 - Article
AN - SCOPUS:85086923426
SN - 0954-6111
VL - 191
JO - Respiratory Medicine
JF - Respiratory Medicine
M1 - 105991
ER -